Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.

Genentech announced that new data were presented at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s ...

About Genentech in neuroscience Neuroscience is a major focus of research and development at Genentech and Roche. Our goal is to pursue groundbreaking science to develop new treatments that help ...

Researchers used UK Biobank data to identify 70 proteins with genetically predicted roles in asthma, offering insights into ...

SOUTH SAN FRANCISCO, Calif., April 03, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data were presented at the AD/PD 2025 ...

No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

M.D., Ph.D., Genentech’s chief medical officer and head of Global Product Development. "These findings reaffirm that the current Ocrevus IV 600 mg is optimally dosed to significantly slow ...

About Genentech in Neuroscience Neuroscience is a major focus of research and development at Genentech. Our goal is to pursue groundbreaking science to develop new treatments that help improve the ...

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle™ AD study – ...